Get the Stockscreener App
18.76
0.32%
-0.06
After Hours:
18.76
Caredx Inc stock is traded at $18.76, with a volume of 661.25K.
It is down -0.32% in the last 24 hours and down -8.84% over the past month.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically it generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.
See More
Previous Close:
$18.82
Open:
$18.55
24h Volume:
661.25K
Relative Volume:
0.91
Market Cap:
$964.88M
Revenue:
$358.00M
Net Income/Loss:
$70.45M
P/E Ratio:
15.73
EPS:
1.1924
Net Cash Flow:
$36.42M
1W Performance:
-0.21%
1M Performance:
-8.84%
6M Performance:
+41.16%
1Y Performance:
-10.92%
1-Day Range:
$18.34
$19.00
1-Week Range:
$17.05
$19.43
52-Week Range:
$10.96
$22.61
Caredx Inc Stock (CDNA) Company Profile
Name
Caredx Inc
Sector
Industry
Phone
415-287-2300
Address
8000 MARINA BLVD, BRISBANE, CA
Compare CDNA vs TMO, DHR, IDXX, A, WAT
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CDNA
Caredx Inc
|
18.76 | 967.96M | 358.00M | 70.45M | 36.42M | 1.1924 |
|
TMO
Thermo Fisher Scientific Inc
|
521.11 | 195.41B | 44.56B | 6.73B | 6.29B | 17.74 |
|
DHR
Danaher Corp
|
210.64 | 148.05B | 24.57B | 3.60B | 5.26B | 5.051 |
|
IDXX
Idexx Laboratories Inc
|
656.73 | 52.76B | 4.30B | 1.06B | 1.04B | 13.08 |
|
A
Agilent Technologies Inc
|
121.38 | 34.22B | 6.95B | 1.30B | 1.15B | 4.5696 |
|
WAT
Waters Corp
|
319.38 | 31.67B | 3.17B | 642.63M | 516.49M | 10.77 |
Caredx Inc Stock (CDNA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-06-26 | Downgrade | Craig Hallum | Buy → Hold |
| Aug-26-25 | Initiated | William Blair | Mkt Perform |
| Jan-15-25 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Aug-28-24 | Initiated | Wells Fargo | Underweight |
| Aug-19-24 | Upgrade | BTIG Research | Neutral → Buy |
| May-13-24 | Downgrade | Raymond James | Outperform → Mkt Perform |
| May-01-24 | Upgrade | Craig Hallum | Hold → Buy |
| Nov-09-23 | Upgrade | Stephens | Equal-Weight → Overweight |
| Aug-15-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| May-11-23 | Downgrade | BTIG Research | Buy → Neutral |
| Mar-07-23 | Downgrade | Stephens | Overweight → Equal-Weight |
| Mar-03-23 | Downgrade | Craig Hallum | Buy → Hold |
| Mar-03-23 | Downgrade | Raymond James | Strong Buy → Mkt Perform |
| Apr-25-22 | Initiated | Stephens | Overweight |
| Jul-20-21 | Resumed | BTIG Research | Buy |
| Jun-03-21 | Initiated | Goldman | Buy |
| Feb-26-21 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Oct-30-20 | Reiterated | H.C. Wainwright | Buy |
| Oct-08-20 | Reiterated | H.C. Wainwright | Buy |
| Oct-02-20 | Reiterated | H.C. Wainwright | Buy |
| Aug-05-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-26-20 | Initiated | BTIG Research | Buy |
| Jun-19-20 | Reiterated | H.C. Wainwright | Buy |
| Oct-01-19 | Resumed | Craig Hallum | Buy |
| May-09-19 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Feb-15-19 | Initiated | Jefferies | Buy |
| Oct-23-18 | Resumed | Raymond James | Strong Buy |
| Sep-18-18 | Reiterated | H.C. Wainwright | Neutral |
| Nov-27-17 | Initiated | H.C. Wainwright | Buy |
| Jun-14-16 | Reiterated | Mizuho | Buy |
| Sep-29-15 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Sep-25-15 | Initiated | Craig Hallum | Buy |
| Mar-18-15 | Reiterated | Mizuho | Buy |
View All
Caredx Inc Stock (CDNA) Latest News
BTIG Raises CareDx (CDNA) Price Target to $26.00, Maintains Buy Rating | CDNA Stock News - GuruFocus
CareDx, Inc Q4 2025 Earnings Call Summary - Yahoo Finance
BTIG raises CareDx stock price target to $26 on strong Q4 results - Investing.com India
CareDx: Conservative Revenue Upside Offset by Weaker Margins and Coverage Uncertainty Justifying Hold Rating - TipRanks
CareDx Names COO to Additional CFO Post - Contract Pharma
CareDx (CDNA) Receives Rating Update: Wells Fargo Raises Price T - GuruFocus
CareDx (NASDAQ:CDNA) Stock Price Expected to Rise, Wells Fargo & Company Analyst Says - MarketBeat
CareDx, Inc (NASDAQ:CDNA) Q4 2025 Earnings Call Transcript - Insider Monkey
CareDx: Fourth Quarter Financial Overview - Bitget
CareDx Inc (CDNA) Q4 2025 Earnings Call Highlights: Strong Reven - GuruFocus
CareDx Q4 Earnings Call Highlights - Yahoo Finance
CareDx names COO Keith Kennedy as chief financial officer - Investing.com India
CareDx (CDNA) Reports Q4 Earnings: What Key Metrics Have to Say - Yahoo Finance
CareDx (CDNA) Q4 Earnings Miss Estimates - Nasdaq
CareDx (CDNA) Announces Key Leadership Change as COO Takes on CF - GuruFocus
CareDx Inc (NASDAQ:CDNA) Reports Strong Revenue Beat but Profitability Concerns Weigh on Shares - ChartMill
Caredx Inc says Keith Kennedy appointed as CFO and COOSEC filing - marketscreener.com
Caredx Inc Says Keith Kennedy Appointed As CFO And COOSEC Filing - TradingView
Caredx announces appointment of Keith Kennedy as chief operating officer and chief financial officer - marketscreener.com
CareDx (CDNA) Exceeds Q4 Revenue Expectations, Eyes Future Growt - GuruFocus
CDNA Forecasts FY26 Adjusted EBITDA Between $30M-$45M - GuruFocus
CareDx names COO Keith Kennedy as chief financial officer By Investing.com - Investing.com UK
CareDx Announces Appointment of Keith Kennedy as Chief Operating Officer and Chief Financial Officer - Business Wire
CareDx Names New CFO Amid Strong Q4 2025 Results - TipRanks
CareDx Q4 Non-GAAP Earnings Fall, Revenue Rises - marketscreener.com
CareDx (CDNA) Q4 2025 Earnings Call Transcript - The Globe and Mail
CareDx: Q4 Earnings Insights - Benzinga
CareDx Announces Fourth Quarter and Full Year 2025 Financial Results - Yahoo Finance
Comparing CareDx (NASDAQ:CDNA) and Elevance Health (NYSE:ELV) - Defense World
Justices Want Natera's Take On CareDx's False Ad Petition - Law360
Uncovering Potential: CareDx's Earnings Preview - Benzinga
AlloHeme Clinical Validation Could Be A Game Changer For CareDx’s (CDNA) Transplant Platform Expansion - Sahm
Growth Review: Should you avoid CareDx Inc stock right now2025 Trading Recap & Free Community Supported Trade Ideas - baoquankhu1.vn
Risk Hedge: Can Navitas Semiconductor Corporation disrupt its industryQuarterly Portfolio Review & Expert Curated Trade Ideas - baoquankhu1.vn
CareDx (CDNA) to Announce Earnings on Tuesday - Defense World
(CDNA) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Stock Report: Is BLUEs ROIC above industry average2025 Price Momentum & Weekly High Conviction Ideas - baoquankhu1.vn
CareDx to Participate in the Raymond James 47th Annual Institutional Investors Conference - BioSpace
Is CareDx (CDNA) Quietly Redefining Its Moat With AlloHeme’s Early Relapse Detection Breakthrough? - Yahoo Finance
FILING DEADLINE--Kuznicki Law PLLC Announces Class Action on Beh - GuruFocus
Zweig DiMenna Associates LLC Buys 348,400 Shares of CareDx, Inc. $CDNA - MarketBeat
CareDx (CDNA) Projected to Post Earnings on Tuesday - MarketBeat
CareDx Reports Positive Data for AlloHeme in AML and MDS Post HCT - Zacks Investment Research
Does ACROBAT AlloHeme Validation Broaden CareDx’s (CDNA) Transplant+ Thesis Into Hematology-Oncology? - simplywall.st
Assessing CareDx (CDNA) Valuation After Positive AlloHeme Clinical Validation Results - Yahoo Finance
CareDx Seeks High Court Review Of $45M False Ad Case - Law360
CareDx Announces Clinical Validation Results for AlloHeme, the First AI-Powered NGS Surveillance Solution for AML and MDS Post-Cell Therapy - marketscreener.com
CareDx Expands “Transplant Plus” Into Cell Therapy, Showcases AlloHeme AML/MDS Relapse Data - MarketBeat
Page not foundAirwhon - MarketBeat
Rate Cut: Can CareDx Inc maintain sales growthPortfolio Value Summary & Fast Momentum Entry Tips - baoquankhu1.vn
Panic Selling: Will CareDx Inc (1K9) stock benefit from infrastructure billQuarterly Trade Review & Risk Managed Investment Strategies - mfd.ru
Caredx Inc Stock (CDNA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.38%
0.76%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):